Higher serum PD‐L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Higher serum PD‐L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial

Published:2020-09-10 Issue:22 Volume:126 Page:4859-4866
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Moku Prashanth¹,Shepherd Lois²,Ali Suhail M.¹³,Leitzel Kim¹,Parulekar Wendy R.²,Zhu Liting²,Virk Shakeel²,Nomikos Dora²,Aparicio Samuel⁴,Gelmon Karen⁴,Drabick Joe¹,Cream Leah¹,Halstead E. Scott¹,Umstead Todd M.¹,Mckeone Dan¹,Polimera Hyma¹^ORCID,Maddukuri Ashok¹,Ali Aamnah¹,Nagabhairu Vinod⁵,Poulose Joyson¹,Pancholy Neha¹,Spiegel Howard⁶,Chen Bingshu E.²,Lipton Allan¹

Affiliation:

1. Penn State Hershey Medical Center Hershey Pennsylvania

2. Canadian Cancer Trials Group Queen's University Kingston Ontario Canada

3. Lebanon VA Medical Center Lebanon Pennsylvania

4. British Columbia Cancer Agency Vancouver British Columbia Canada

5. Pinnacle Health Harrisburg Pennsylvania

6. ProteinSimple San Jose California

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33149

Reference38 articles.

1. American Cancer Society.Cancer Statistics Center. Accessed May 7 2020.https://cancerstatisticscenter.cancer.org/#!/

2. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

3. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation

4. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients

5. Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma Exchange May Enhance Antitumor Effects by Removal of Soluble Programmed Death-Ligand 1 and Extracellular Vesicles: Preliminary Study;Biomedicines;2022-10-05

2. Circulating proteins as predictive and prognostic biomarkers in breast cancer;Clinical Proteomics;2022-07-11

3. Challenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics;Breast Cancer: Targets and Therapy;2021-10

4. Decreased levels of circulating cytokines VEGF, TNF-β and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients;Scientific Reports;2021-01-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3